Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

<p>Supplementary Figure 1</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Vishwajith Sridharan (15047154) (author)
مؤلفون آخرون:	Azfar Neyaz (15047157) (author), Abhijit Chogule (15047160) (author), Islam Baiev (15047163) (author), Stephanie Reyes (15047166) (author), Emily G. Barr Fritcher (15047169) (author), Jochen K. Lennerz (15014703) (author), William Sukov (15047172) (author), Benjamin Kipp (15047175) (author), David T. Ting (15018716) (author), Vikram Deshpande (15047178) (author), Lipika Goyal (15047181) (author)
منشور في:	2025
الموضوعات:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Gastrointestinal Cancers Immunotherapy Checkpoint blockade Precision Medicine Translational Research
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
حسب: Evan C. Chen (15054014)
منشور في: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
حسب: Evan C. Chen (15054014)
منشور في: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
حسب: Evan C. Chen (15054014)
منشور في: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
حسب: Evan C. Chen (15054014)
منشور في: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
حسب: Evan C. Chen (15054014)
منشور في: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
حسب: Evan C. Chen (15054014)
منشور في: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
حسب: Jiachun Su (16990970)
منشور في: (2025)

Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
حسب: Joel R. Eisner (15132120)
منشور في: (2025)

Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
حسب: Joel R. Eisner (15132120)
منشور في: (2025)

Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
حسب: Joel R. Eisner (15132120)
منشور في: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
حسب: Nicholas T. Younger (14956251)
منشور في: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
حسب: Nicholas T. Younger (14956251)
منشور في: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
حسب: Nicholas T. Younger (14956251)
منشور في: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
حسب: Nicholas T. Younger (14956251)
منشور في: (2025)

Genetic variation and mRNA expression of the <i>ELOVL6</i> and <i>CRTC2</i> genes in Kalmyk cattle
حسب: Nurlybay Kazhgaliyev (9904228)
منشور في: (2025)

APP deficiency did not affect the mRNA level of <i>Scn8a</i> in cerebellar PCs.
حسب: Miao-Jin Ji (22676552)
منشور في: (2025)

Figure 1 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
حسب: Natalie C. Fisher (15046025)
منشور في: (2025)

Figure 2 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
حسب: Natalie C. Fisher (15046025)
منشور في: (2025)

Figure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
حسب: Natalie C. Fisher (15046025)
منشور في: (2025)

Figure 4 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
حسب: Natalie C. Fisher (15046025)
منشور في: (2025)

Figure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
حسب: Natalie C. Fisher (15046025)
منشور في: (2025)

Figure 6 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
حسب: Natalie C. Fisher (15046025)
منشور في: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
حسب: Carlotta Antoniotti (15352506)
منشور في: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
حسب: Carlotta Antoniotti (15352506)
منشور في: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
حسب: Carlotta Antoniotti (15352506)
منشور في: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
حسب: Katie E. Hebron (15046889)
منشور في: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
حسب: Katie E. Hebron (15046889)
منشور في: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
حسب: Katie E. Hebron (15046889)
منشور في: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
حسب: Katie E. Hebron (15046889)
منشور في: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
حسب: Katie E. Hebron (15046889)
منشور في: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
حسب: Katie E. Hebron (15046889)
منشور في: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
حسب: Katie E. Hebron (15046889)
منشور في: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
حسب: Ruth Flümann (15123900)
منشور في: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
حسب: Ruth Flümann (15123900)
منشور في: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
حسب: Ruth Flümann (15123900)
منشور في: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
حسب: Ruth Flümann (15123900)
منشور في: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
حسب: Ruth Flümann (15123900)
منشور في: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
حسب: Ruth Flümann (15123900)
منشور في: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
حسب: Chong Kin Liam (15331321)
منشور في: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
حسب: Chong Kin Liam (15331321)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_6tg1ng7kbqrkkbpr7npt2eahba